| Filed On | Filing |
|---|---|
| 10 Nov 2026 | SCHEDULE 13G |
| 09 Nov 2026 | FORM 10-Q |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today ... |
| 02 Oct 2026 |
Form 4: Lerner Neil, Chief Accounting Officer
Bought 20,000 shares ($18.4K) |
| 25 Sep 2026 |
Form 4: Lerner Neil, Chief Accounting Officer
Bought 2,500 shares ($2.85K) |
| 22 Sep 2026 |
8-K: Regulation FD Disclosure
BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today... |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 07 Aug 2026 | SCHEDULE 13G |
| 06 Aug 2026 | FORM 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today ... |
| 01 Jul 2026 |
8-K: Regulation FD Disclosure
1 Nasdaq: CMPX Bringing Transformative Oncology Therapies to Patients Corporate Presentation I July 2026 |
| 23 Jun 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by the... |
| 11 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 10, 2026 Compass Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders. The final results for each of the matters submitted to a vote of stockholders at the meeting are set forth below. A more detailed descri... |
| 15 May 2026 | SCHEDULE 13G/A |
| 05 May 2026 | FORM 10-Q |
| 05 May 2026 |
8-K: Results of Operations and Financial Condition
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today r... |
| 30 Apr 2026 |
Form 4/A: Anderman Jonathan, General Counsel
Bought 25,000 shares ($47.3K) |
| 30 Apr 2026 |
Form 4/A: Lerner Neil, Chief Accounting Officer
Bought 15,000 shares ($28.4K) |
| 29 Apr 2026 |
Form 4: Anderman Jonathan, General Counsel
Received 25,000 shares as a grant or award ($47.3K) |
| 29 Apr 2026 |
Form 4: Lerner Neil, Chief Accounting Officer
Received 15,000 shares as a grant or award ($28.4K) |
Loading...